We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA served Alkermes with a warning letter for serious violations in the promotion of its opioid addiction treatment Vivitrol (naltrexone for extended-release injectable suspension). Read More